Dyadic International Inc. (NASDAQ:DYAI) Sees Large Decline in Short Interest

Dyadic International Inc. (NASDAQ:DYAI) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 83,534 shares, a decline of 52.2% from the June 30th total of 174,705 shares. Based on an average daily trading volume, of 326,346 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the company’s stock are short sold.

Hedge Funds Weigh In On Dyadic International

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares during the period. Marathon Capital Management lifted its position in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 50,000 shares during the period. Landscape Capital Management L.L.C. acquired a new position in Dyadic International during the third quarter valued at $190,000. Finally, Bank of America Corp DE boosted its holdings in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. 27.95% of the stock is owned by hedge funds and other institutional investors.

Dyadic International Stock Performance

NASDAQ:DYAI traded up $0.04 during trading hours on Wednesday, hitting $1.10. 72,048 shares of the company were exchanged, compared to its average volume of 180,796. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. Dyadic International has a 52-week low of $0.65 and a 52-week high of $1.60. The stock has a market capitalization of $40.27 million, a price-to-earnings ratio of -4.80 and a beta of 1.15. The company’s 50 day moving average price is $0.91 and its 200-day moving average price is $0.85.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, research analysts forecast that Dyadic International will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dyadic International currently has a consensus rating of “Hold” and an average target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.